Sarah Gregory1, James H Cole2,3, Ruth E Farmer4, Elin M Rees2, Raymund A C Roos5, Reiner Sprengelmeyer6, Alexandra Durr7, Bernhard Landwehrmeyer6, Hui Zhang8, Rachael I Scahill2, Sarah J Tabrizi2, Chris Frost4, Nicola Z Hobbs2,9. 1. Wellcome Trust Centre for Neuroimaging, UCL, London, WC1N 3BG, UK. 2. UCL Institute of Neurology, University College London, UK. 3. Computational, Cognitive & Clinical Neuroimaging Laboratory, Department of Medicine, Imperial College London, UK. 4. Department of Medical Statistics, London School of Hygiene & Tropical Medicine London, UK. 5. Department of Neurology, Leiden University Medical Centre, 2300RC Leiden, The Netherlands. 6. Department of Neurology, Ulm University, Ulm, Germany. 7. Department of Genetics and Cytogenetics, INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France. 8. Centre for Medical Image Computing, University College London, UK. 9. IXICO Plc., London, UK.
Abstract
BACKGROUND: Huntington's disease is marked by progressive neuroanatomical changes, assumed to underlie the development of the disease's characteristic symptoms. Previous work has demonstrated longitudinal macrostructural white-matter atrophy, with some evidence of microstructural change focused in the corpus callosum. OBJECTIVE: To more accurately characterise longitudinal patterns, we examined white matter microstructural change using Diffusion Tensor Imaging (DTI) data from three timepoints over a 15 month period. METHODS: In 48 early-stage HD patients and 36 controls from the multi-site PADDINGTON project, diffusion tensor imaging (DTI) was employed to measure changes in fractional anisotropy (FA) and axial (AD) and radial diffusivity (RD) in 24 white matter regions-of-interest (ROIs). RESULTS: Cross-sectional analysis indicated widespread baseline between-group differences, with significantly decreased FA and increased AD and RD found in HD patients across multiple ROIs. Longitudinal rates of change differed significantly between HD patients and controls in the genu and body of corpus callosum, corona radiata and anterior limb of internal capsule. Change in RD in the body of the corpus callosum was significantly associated with baseline disease burden, but other clinical associations were not significant. CONCLUSIONS: We detected subtle longitudinal white matter changes in early HD patients. Progressive white matter abnormalities in HD may not be uniform throughout the brain, with some areas remaining static in the early symptomatic phase. Longer assessment periods across disease stages will help map this progressive trajectory.
BACKGROUND:Huntington's disease is marked by progressive neuroanatomical changes, assumed to underlie the development of the disease's characteristic symptoms. Previous work has demonstrated longitudinal macrostructural white-matter atrophy, with some evidence of microstructural change focused in the corpus callosum. OBJECTIVE: To more accurately characterise longitudinal patterns, we examined white matter microstructural change using Diffusion Tensor Imaging (DTI) data from three timepoints over a 15 month period. METHODS: In 48 early-stage HDpatients and 36 controls from the multi-site PADDINGTON project, diffusion tensor imaging (DTI) was employed to measure changes in fractional anisotropy (FA) and axial (AD) and radial diffusivity (RD) in 24 white matter regions-of-interest (ROIs). RESULTS: Cross-sectional analysis indicated widespread baseline between-group differences, with significantly decreased FA and increased AD and RD found in HDpatients across multiple ROIs. Longitudinal rates of change differed significantly between HDpatients and controls in the genu and body of corpus callosum, corona radiata and anterior limb of internal capsule. Change in RD in the body of the corpus callosum was significantly associated with baseline disease burden, but other clinical associations were not significant. CONCLUSIONS: We detected subtle longitudinal white matter changes in early HDpatients. Progressive white matter abnormalities in HD may not be uniform throughout the brain, with some areas remaining static in the early symptomatic phase. Longer assessment periods across disease stages will help map this progressive trajectory.
Authors: Vincent Pozorski; Jennifer M Oh; Nagesh Adluru; Andrew P Merluzzi; Frances Theisen; Ozioma Okonkwo; Amy Barzgari; Stephanie Krislov; Jitka Sojkova; Barbara B Bendlin; Sterling C Johnson; Andrew L Alexander; Catherine L Gallagher Journal: Hum Brain Mapp Date: 2018-06-27 Impact factor: 5.038
Authors: Deborah L Harrington; Jeffrey D Long; Sally Durgerian; Lyla Mourany; Katherine Koenig; Aaron Bonner-Jackson; Jane S Paulsen; Stephen M Rao Journal: Mov Disord Date: 2016-09-13 Impact factor: 10.338
Authors: Iain D Croall; Valerie Lohner; Barry Moynihan; Usman Khan; Ahamad Hassan; John T O'Brien; Robin G Morris; Daniel J Tozer; Victoria C Cambridge; Kirsty Harkness; David J Werring; Andrew M Blamire; Gary A Ford; Thomas R Barrick; Hugh S Markus Journal: Clin Sci (Lond) Date: 2017-06-07 Impact factor: 6.124
Authors: Jiaying Zhang; Sarah Gregory; Rachael I Scahill; Alexandra Durr; David L Thomas; Stéphane Lehericy; Geraint Rees; Sarah J Tabrizi; Hui Zhang Journal: Ann Neurol Date: 2018-09-15 Impact factor: 10.422
Authors: Marios C Yiannakas; Francesco Grussu; Polymnia Louka; Ferran Prados; Rebecca S Samson; Marco Battiston; Daniel R Altmann; Sebastien Ourselin; David H Miller; Claudia A M Gandini Wheeler-Kingshott Journal: PLoS One Date: 2016-10-14 Impact factor: 3.240
Authors: Nikoletta Szabó; Péter Faragó; András Király; Dániel Veréb; Gergő Csete; Eszter Tóth; Krisztián Kocsis; Bálint Kincses; Bernadett Tuka; Árpád Párdutz; Délia Szok; János Tajti; László Vécsei; Zsigmond T Kincses Journal: Front Neuroanat Date: 2018-01-17 Impact factor: 3.856